Exploring the role of Aspergillus galactomannan antigen in assessing the risk factor of acute exacerbations in chronic obstructive pulmonary disease patients: a cross-sectional study
Open Access
- 12 September 2024
- journal article
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 95 (3)
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by permanent airflow obstruction due to abnormalities of the airways and alveoli. This study investigated the potential role of Aspergillus species in acute exacerbations of COPD (AE-COPD) and evaluated the diagnostic utility of serum Aspergillus galactomannan antigen. This cross-sectional study, carried out at the Jawaharlal Institute of Postgraduate Medical Education and Research from January 2021 to June 2022, involved COPD patients aged ≥40 years. Serum galactomannan and serum Aspergillus-specific antibodies were analyzed, along with the collection of demographic details, symptoms, and comorbidities. Statistical analyses, including univariate analysis and receiver operating characteristic (ROC) curve analysis, were performed. Among the 61 recruited COPD patients, 24.5% showed serum galactomannan positivity. Significant associations were found between galactomannan positivity, hemoptysis, and previous tuberculosis. ROC analysis revealed modest diagnostic accuracy (area under the ROC=0.6027) with a sensitivity of 44.4% and a specificity of 83.7% at a cut-off of 0.5. Univariate analysis did not show any potential links between diabetes, hypertension, previous exacerbations, and severe Global Initiative for Chronic Obstructive Lung Disease stages with a risk of exacerbation. Serum galactomannan antigen showed limited sensitivity, and its routine testing may not be justified for predicting exacerbation risk. Further studies are warranted to validate these findings and explore other diagnostic methods using bronchoalveolar lavage galactomannan antigen in AE-COPD.Keywords
This publication has 27 references indexed in Scilit:
- Detection of serum Aspergillus-specific IgM and IgG antibody levels for the diagnosis of chronic pulmonary aspergillosis developed in patients with tuberculosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2023
- Improving lung health in low-income and middle-income countries: from challenges to solutionsThe Lancet, 2021
- Smoking as a Risk Factor of Invasive Fungal Disease: Systematic Review and Meta-AnalysisClinical Infectious Diseases, 2020
- The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosisRespiratory Medicine, 2013
- Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosisClinical Microbiology and Infection, 2013
- Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stageJournal of Infection, 2012
- Changes in Forced Expiratory Volume in 1 Second over Time in COPDNew England Journal of Medicine, 2011
- Serum and Bronchoalveolar Lavage Fluid Galactomannan Assays in Patients with Pulmonary AspergillomaClinical Infectious Diseases, 2011
- Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosisThe Lancet Infectious Diseases, 2004
- False-positive results of Aspergillus enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantationBone Marrow Transplantation, 2001